NDLI: Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole

Please wait, while we are loading the content...

Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole

Impact of SOX18 expression in cancer cells and vessels on the outcome of invasive ductal breast carcinoma

Increase in ezrin expression from benign to malignant breast tumours

Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway

Macrophages as potential targets for zoledronic acid outside the skeleton—evidence from in vitro and in vivo models

SiRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells

Cellular Oncology : Volume 36, Issue 5, October 2013

Cellular Oncology : Volume 36, Issue 4, July 2013

Cellular Oncology : Volume 36, Issue 3, June 2013

Cellular Oncology : Volume 36, Issue 2, April 2013

Cellular Oncology : Volume 36, Issue 1, February 2013

Cellular Oncology : Volume 35

Cellular Oncology : Volume 34

Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole

Content Provider	Springer Nature Link
Author	Rawat, Akhilesh Gopal, Gopisetty Selvaluxmy, Ganesharaja Rajkumar, Thangarajan
Copyright Year	2013
Abstract	The objective of this study was to determine radiation, doxorubicin, tamoxifen and letrozole sensitivity of breast cancer cells in response to functional inhibition of the ubiquitin conjugating enzyme UBE2C.Taqman Real time PCR was performed to measure UBE2C levels in breast cancer cell lines and control HBL100 and HEK293T cells. A dominant negative form of UBE2C (DN-UBE2C) was used to functionally inhibit wild type UBE2C. Cell proliferation and anchorage independent growth were measured by colorimetric and soft agar assays, respectively. Radiation, doxorubicin, tamoxifen and letrozole responses of the cell lines were assessed by colorimetric and clonogenic assays.Overexpression of UBE2C was observed in all breast cancer cell lines tested using quantitative real time PCR. UBE2C expression was found to be highest in MDAMB231 and relatively lowest in MCF7 cells, compared to control cells. Both the growth rate and the anchorage independent growth of MCF7 and MDAMB231 cells transfected with DN-UBE2C were significantly reduced compared to cells transfected with vector alone. MCF7 and MDAMB231 cells expressing DN-UBE2C were significantly more sensitive to different doses of radiation and doxorubicin compared to both wild type and vector alone transfected cells. In addition, DN-UBE2C transfected MCF7 cells were more sensitive to inhibition by tamoxifen and letrozole compared to wild type and vector alone transfected cells.Our results show that inhibition of UBE2C sensitizes breast cancer cells to radiation, doxorubicin and hormone blocking agents. UBE2C may, therefore, serve as a potential therapeutic target aimed at inducing radiation and chemo sensitization.
Starting Page	459
Ending Page	467
Page Count	9
File Format	PDF
ISSN	22113428
Journal	Cellular Oncology
Volume Number	36
Issue Number	6
e-ISSN	22113436
Language	English
Publisher	Springer Netherlands
Publisher Date	2013-09-27
Publisher Institution	International Society for Cellular Oncology
Publisher Place	Dordrecht
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	UBE2C Breast cancer Radiation sensitivity Doxorubicin sensitivity Tamoxifen sensitivity Letrozole sensitivity Therapeutic target Cancer Research Biomedicine general Pathology Oncology
Content Type	Text
Resource Type	Article
Subject	Cancer Research Molecular Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression

Pharmacological inhibition of AKT sensitizes MCF-7 human breast cancer-initiating cells to radiation

Letrozole sensitizes breast cancer cells to ionizing radiation

SiRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells

Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma

High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression

Ubiquitin-Conjugating Enzymes in Cancer

The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data

Male breast carcinoma: increased awareness needed

Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole

Similar Documents

High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression

Pharmacological inhibition of AKT sensitizes MCF-7 human breast cancer-initiating cells to radiation

Letrozole sensitizes breast cancer cells to ionizing radiation

SiRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells

Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma

High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression

Ubiquitin-Conjugating Enzymes in Cancer

The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data

Male breast carcinoma: increased awareness needed

Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole